Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon
Acta Pharmaceutica Sinica B · 2025-03 · 15 (3) · 1311-1332
DOI: 10.1016/j.apsb.2025.01.023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-03. Verfasst von Martin Kufa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy in Hradec Kralové, Charles University, Hradec Kralove 50003, Czech Republic. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Hospital Hradec Kralove, Grantová Agentura, Univerzita Karlova, Ministry of Health of the Czech Republic.
Abstract (Originalsprache)
Tuberculosis (TB), an infectious disease caused by the bacterium Mycobacterium tuberculosis (Mtb), was responsible for the deaths of approximately 1.3 million people in 2022. In addition, 7.5 million new cases of TB have been reported. Present-day treatments require a daily dosing of a multiple-drug regimen for a minimum of six-month, but poor adherence and other factors often lead to treatment failure. Consequently, drug-resistant TB strains have become a growing concern, leading to more complex and expensive treatments. Promising drugs such as bedaquiline, delamanid, and pretomanid have been recently released, and 19 drug candidates are currently at different phases of clinical trials, addressing the problem of drug-resistant TB. Notwithstanding recent advances, the development of effective and safe drugs with novel mechanisms of action remains a challenge due to the unique nature of Mtb. Despite the persistent need for new treatments, TB research remains underfunded, highlighting the importance of collaborations between academia and the private sector in the advancement of anti-TB drug development. This review provides a perspective on the dynamic landscape of anti-TB drug discovery in recent years, offering hope for a more effective approach to combat this persistent global health threat.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Pharmacy in Hradec Kralové, Charles University, Hradec Kralove 50003, Czech Republic.
- Biomedical Research Center, University Hospital Hradec Kralove, Hradec Kralove 50003, Czech Republic.
- U.S. Army CCDC Chemical Biological Center, MD 21010-5424, USA.
Förderung
- University Hospital Hradec Kralove
- Grantová Agentura, Univerzita Karlova
- Ministry of Health of the Czech Republic
- European Commission
- Charles University
Zitieren
APA
Kufa, M., Finger, V., Kovar, O., Soukup, O., Torruellas, C., Roh, J., & Korabecny, J. (2025). Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon. Acta Pharmaceutica Sinica B, 15(3), 1311-1332. https://doi.org/10.1016/j.apsb.2025.01.023
Vancouver
Kufa M, Finger V, Kovar O, Soukup O, Torruellas C, Roh J, et al. Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon. Acta Pharmaceutica Sinica B. 2025;15(3):1311-1332. doi:10.1016/j.apsb.2025.01.023
BibTeX
@article{Kufa2025,
author = {Kufa, Martin and Finger, Vladimir and Kovar, Ondrej and Soukup, Ondrej and Torruellas, Carilyn and Roh, Jaroslav and Korabecny, Jan},
title = {Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon},
journal = {Acta Pharmaceutica Sinica B},
year = {2025},
volume = {15},
number = {3},
pages = {1311--1332},
doi = {10.1016/j.apsb.2025.01.023}
}
EUVIMED